Physician profile
Danielle S Mcdermott
NPI 1619139243
$31,496.56
in general payments reported to CMS, 2019-2025
11 companies · $1,085 in 2025
The $1,085 reported for 2025 was more than what a typical Epilepsy provider received nationally (typical 2025 total: $366).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.40 · 2020: $11K · 2021: $17K · 2023: $922 · 2024: $1,127 · 2025: $1,085.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,825 · Food and Beverage: $1,310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,824.56 |
| Food and Beverage | $1,309.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $26,175.21 | 2020-2025 | |
| Neuropace, INC. | $2,883.27 | 2019-2025 | |
| Livanova USA, INC. | $1,432.80 | 2023-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Medtronic, INC. | $368.01 | 2021 | |
| Ucb, INC. | $251.65 | 2020-2025 | Fintepla, Briviact |
| Teva Pharmaceuticals USA, INC. | $133.51 | 2024 | Austedo Xr |
| Neurelis, INC. | $126.00 | 2023-2025 | Valtoco |
| Greenwich Biosciences, INC. | $42.00 | 2021 | |
| Medtronic USA, INC. | $38.17 | 2020 | |
| Jazz Pharmaceuticals INC. | $23.14 | 2023 | |
| Eisai INC. | $22.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Mcdermott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.